Stabilitech BioPharma

Redefining the way we make and take vaccines.  








  • Millions of people infected.
  • Billions of people affected.
  • Trillions of dollars invested.

The world is fighting back.

Stabilitech is part of that fight.

The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.

The Los Angeles Times’ Ralph Vartabedian says:

“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”

Thermally stable, self-administered vaccines in capsule form are the future



Imagine a world where all vaccines are taken as a capsule – with no needles, no need for cold storage and reduced dependency on healthcare professionals.

OraPro™ is an oral delivery vaccine platform. It effectively delivers non-replicating viral vectors to the gastrointestinal (GI) tract to elicit effective immunity against infectious diseases but not the viral vector itself. Stabilitech is using OraPro to develop the world’s first oral COVID-19 and Zika vaccines. Research is also underway to develop oral vaccines for several other key diseases, including OraPro-Shingles to provide immunity to the Varicela Zoster Virus, which is affects 1 in 4 adults in their lifetime and was estimated to be worth $2 billion in 2019.

Discover more about OraPro and our oral vaccine development programme


COVID-19 is the perfect example of a novel virus with the ability to rapidly cause a pandemic. In the case of a highly infectious novel virus, the swift development of a vaccine is not enough. An effective vaccine needs to deliver mucosal and systemic immunity combined with how quickly an entire population can be vaccinated.

Using OraPro technology, Stabilitech’s OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.

Discover more about OraPro-COVID-19™


Novel oral protein therapeutic
Multi-strain influenza vaccine
VZV product exempler
Reduce antigen requirement
by up to 99%
Thermally stable vaccines
Faster onset of immunity
using less vaccine

Stabilitech takes next step in race for a vaccine, announces BioCell as manufacturer for OraPro-COVID-19



Burgess Hill, UK, 12 June 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today a partnership with BioCell Corporation (New Zealand) to manufacture its oral coronavirus vaccine, OraPro-COVID-19.

The Auckland-based company has 30 years’ experience in manufacturing viral vaccines, with its recent acquisition of Living Cell Technology’s GMP compliant cell culture facility providing dedicated premises for the manufacturing of COVID-19 vaccines.

“After a successful recent fundraising round, this signed agreement represents a crucial next step for OraPro-COVID-19,” said Stabilitech’s Chairman Wayne Channon. “It brings us closer to providing a vaccine that gives both mucosal and systemic immunity to COVID-19. This will target the virus exactly where we catch it: in the mucous membranes of the mouth, nose, throat and even the eyes. By taking this approach, we believe OraPro-COVID-19 could prove to provide the fastest route to widespread global immunity, turning the tide on the pandemic.”

Human trials for Stabilitech’s potential breakthrough vaccine are scheduled for August of this year. If successful, the deal signed with BioCell means that a vaccine could be available by the end of 2020.

“We are delighted to be working with Stabilitech to manufacture a vaccine for COVID-19,” explained BioCell’s CEO Nidish Nair. “Our team includes three award winning scientists, as well as a host of other highly skilled technical employees, who will all be working to enhance technology transfer and process development for Ora-Pro-COVID-19. The partnership also represents a great opportunity for New Zealand to play a part in the race for a COVID-19 vaccine, further highlighting our ability to undertake internationally recognised research and manufacturing projects.”

While there are over 100 other companies and institutions working towards what UN Secretary-General António Guterres dubbed at the recent GAVI World Vaccine Summit

as “the people’s vaccine”, reaching the manufacturing stage is an indicator of Ora-Pro-COVID-19’s potential. The deal also shines a light on the great strides that smaller biopharma companies around the world are making in the race for a COVID-19 vaccine.

For further information about the science behind OraPro-COVID-19 and interview opportunities with Wayne Channon, please contact:


Downloadable media assets

Press release docFull Zip Download
Stabilitech takes next step in race for a vaccine, announces BioCell as manufacturer for OraPro-COVID-19 Logo

Stabilitech Biopharma earns prestigious position on WHO list of vaccine developers



Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals,  announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer.

In addition to this global recognition, two Stabilitech board members, Dr Jeff Drew and Dr Elliot Bland were invited to participate in the Expert Group meetings on “Assays Development for Vaccines” and “Animal Models”.

This news is welcomed as, last week the company announced that it is currently in the process of securing further investment for its unique oral vaccine (OraPro-COVID-19 vaccine) that offers double immunity targeting both systemic and mucosal cells. In capsule form, the vaccine is self-administered and requires no cold chain storage.

Speaking on the appointment, Dr Drew highlighted: “The WHO is a pivotal player when it comes to vaccines, it sets all of the guidelines adopted by bio-pharmaceutical companies for vaccines development. Being added to the WHO’s list as a recognised vaccine developer is huge news for us and the UK biopharma sector, providing a level of global recognition that Stabilitech is an active player in finding a vaccine for COVID-19.”

“This is an important role contributing to the development of vaccines globally. Stabilitech’s expertise can be combined with those at other leading organisations such as Imperial College and Oxford,” added Dr Bland.

Dr Bland concludes: “The COVID-19 pandemic is a global challenge that requires international collaboration to find a solution. Joining the taskforce committee, means Stabilitech has direct input into COVID-19 vaccine development, making us part of the global community fight against Coronavirus.”



Downloadable media assets

Press release docFull Zip Download
Stabilitech Biopharma recognised position on WHO list of Vaccine Developers and participates in two expert group meetings to find a viable vaccine for COVID-19.Stabilitech_press_release_media_downloadStabilitech Logo